Updated AHA/ACC Chest Pain Guidelines

Low-risk chest pain rarely benefits from urgent stress testing or cardiac imaging. The 2021 AHA/ACC chest pain guideline leans on high-sensitivity troponin and structured pathways to define low risk, while shared decision-making, ECG nuance, and selective testing remain where bedside judgment matters most.

Low-Risk Chest Pain Strategy

• Low-risk outcome threshold: The guideline defines low risk as under 1% 30-day risk of death or major adverse cardiac events, making routine urgent testing unnecessary in that group.
• No routine stress testing: For low-risk acute or stable chest pain, stress testing and coronary imaging within 30 days have not shown outcome benefit; the real priority is risk-factor modification.
• High-sensitivity troponin preference: High-sensitivity troponin is the preferred biomarker because it accelerates rule-out and improves ED throughput with 1- to 2-hour repeat strategies, though downstream testing remains a concern.
• Clinical pathway definitions: The guideline endorses pathways like HEART and EDACS to identify low-risk patients, but the external validity and true outcome benefit are less certain than the recommendation sounds. We get into that tension in the episode.
• Shared decision-making role: For intermediate-risk patients, shared decision-making is a formal recommendation because it improves understanding and reduces low-value testing while better matching care to patient risk tolerance.

Nuance the Guideline Misses

• Subtle occlusion MI patterns: STEMI criteria miss important occlusion MI equivalents, and the update gives little practical guidance beyond new ST elevation, ST depression, or new left bundle branch block.
• Focused echo limitations: Bedside TTE is useful in intermediate-risk chest pain for wall-motion abnormalities, ventricular function, valve complications, and pericardial effusion, but its discharge-risk role is much less clear.
• Atypical chest pain language: The guideline discourages the term atypical chest pain, favoring cardiac, possibly cardiac, and noncardiac labels, but symptom descriptors like exertional pressure versus pleuritic fleeting pain are often more useful.
• Selective chest radiography: Chest x-ray should be guided by clinical suspicion rather than reflex ordering, because it often does not reveal an intervention-requiring diagnosis despite broad guideline wording.
• Testing warranty skepticism: The proposed warranty periods for prior normal stress tests and coronary imaging are controversial, especially given the limited sensitivity of exercise stress testing and plaque biology. We walk through why that matters in the chapter.

References:

1. Morgenstern, J. Key Updates from the 2021 AHA Guideline for the Evaluation and Diagnosis of Chest Pain, First10EM, March 14, 2022. Link.
2. Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Nov 30;78(22):e187-e285. PMID: 34756653.
3. Chew DP, et al. A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes: The Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High-Sensitivity Troponin T Study (RAPID-TnT). Circulation. 2019 Nov 5;140(19):1543-1556.PMID: 31478763.
4. Shah ASV, et al; High-STEACS Investigators. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet. 2018 Sep 15;392(10151):919-928. PMID: 30170853.